Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer.
Bladder cancer
Cell-free DNA
Depth of invasion
Journal
Current urology
ISSN: 1661-7649
Titre abrégé: Curr Urol
Pays: United States
ID NLM: 101471188
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
07
03
2022
accepted:
15
11
2022
medline:
23
11
2023
pubmed:
23
11
2023
entrez:
23
11
2023
Statut:
ppublish
Résumé
Radical cystectomy (RC) is the standard surgical treatment for patients with muscle-invasive bladder cancer, but the prognosis is not favorable, and new prognostic factors need to be discovered. We investigated the potential of depth of invasion (DOI) as a prognostic factor in patients with muscle-invasive bladder cancer who underwent RC. Furthermore, we examined the association between preoperative levels of circulating cell-free DNA and DOI. We retrospectively reviewed patients who underwent RC between January 2007 and December 2017; those who received neoadjuvant chemotherapy were excluded. Depth of invasion was measured using hematoxylin-eosin-stained RC specimens. Of the 121 patients selected, 41 (33.9%) were eligible for analysis. The median follow-up period was 14 months and mean DOI was 17 mm (range, 2-75 mm). Long DOI (>17 mm) was significantly associated with shorter progression-free survival (hazard ratio, 14.5; 95% confidence interval, 3.9-53.97, Depth of invasion predicted with levels of circulating cell-free DNA and thus could be a useful prognostic factor.
Sections du résumé
Background
UNASSIGNED
Radical cystectomy (RC) is the standard surgical treatment for patients with muscle-invasive bladder cancer, but the prognosis is not favorable, and new prognostic factors need to be discovered. We investigated the potential of depth of invasion (DOI) as a prognostic factor in patients with muscle-invasive bladder cancer who underwent RC. Furthermore, we examined the association between preoperative levels of circulating cell-free DNA and DOI.
Materials and methods
UNASSIGNED
We retrospectively reviewed patients who underwent RC between January 2007 and December 2017; those who received neoadjuvant chemotherapy were excluded. Depth of invasion was measured using hematoxylin-eosin-stained RC specimens.
Results
UNASSIGNED
Of the 121 patients selected, 41 (33.9%) were eligible for analysis. The median follow-up period was 14 months and mean DOI was 17 mm (range, 2-75 mm). Long DOI (>17 mm) was significantly associated with shorter progression-free survival (hazard ratio, 14.5; 95% confidence interval, 3.9-53.97,
Conclusions
UNASSIGNED
Depth of invasion predicted with levels of circulating cell-free DNA and thus could be a useful prognostic factor.
Identifiants
pubmed: 37994338
doi: 10.1097/CU9.0000000000000193
pii: CURR-UROL_230109
pmc: PMC10662802
doi:
Types de publication
Journal Article
Langues
eng
Pagination
229-235Informations de copyright
Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Gene Ther. 2002 Oct;9(19):1302-11
pubmed: 12224013
Am J Transl Res. 2018 Jul 15;10(7):1935-1948
pubmed: 30093933
Eur Urol. 2010 Jul;58(1):112-7
pubmed: 20097469
Cancer. 2003 Sep 1;98(5):955-61
pubmed: 12942562
Urol Oncol. 2013 Nov;31(8):1744-50
pubmed: 23141783
J Clin Oncol. 2004 Oct 15;22(20):4157-64
pubmed: 15483026
Oncotarget. 2017 Apr 18;8(16):26625-26636
pubmed: 28460452
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer. 2012 Jan 1;118(1):82-90
pubmed: 21713763
Res Rep Urol. 2018 Dec 14;10:251-261
pubmed: 30588457
Cancer Res. 1977 Mar;37(3):646-50
pubmed: 837366
Sci Rep. 2015 Jul 27;5:12171
pubmed: 26212449
J Ovarian Res. 2017 Nov 13;10(1):75
pubmed: 29132396
Histopathology. 2017 Jul;71(1):5-11
pubmed: 28239904
Cancer Res. 2001 Feb 15;61(4):1659-65
pubmed: 11245480
Urology. 2007 Sep;70(3):477-81
pubmed: 17905100
Int J Urol. 2015 Aug;22(8):742-6
pubmed: 25988857
Eur Urol. 2012 Feb;61(2):378-84
pubmed: 22036775
Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71
pubmed: 8118388
Oncology. 1989;46(5):318-22
pubmed: 2779946
Anticancer Res. 2010 Jun;30(6):2235-40
pubmed: 20651374
Urol Oncol. 2016 Jun;34(6):257.e11-7
pubmed: 27038696
Science. 1991 May 3;252(5006):706-9
pubmed: 2024123
J Urol. 2006 Dec;176(6 Pt 1):2414-22; discussion 2422
pubmed: 17085118
J Urol. 2013 Apr;189(4):1275-81
pubmed: 23123368
J Urol. 2012 Mar;187(3):1071-9
pubmed: 22266013
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1138-48
pubmed: 25075712
Int J Urol. 2014 Jan;21(1):52-7
pubmed: 23711293
Prostate. 2008 Jan 1;68(1):42-9
pubmed: 18004747